Introduction
Phospholipids containing polyunsaturated fatty acids are highly prone to modification by reactive oxygen species. They readily undergo peroxidation under various conditions and various states of diseases to afford oxidized phospholipids (oxPls), which induce cytotoxicity and apoptosis and may have a significant role in inflammation. Bioactive species comprise phospholipids with extensively modified or truncated fatty acid chains in the sn-2 position typically carrying polar terminal carboxylic or aldehydic groups required for certain biological activities of the agents (Fig. 1 ) [1] .
Peroxidation thus greatly alters the physicochemical properties of membrane lipid bilayers and as a consequence induces signalling dependent on the formation or reorganization of membrane domains or specific molecular binding. OxPl may also affect the pharmacokinetics of drugs. Kinnunen and colleagues [2] found that oxidized phospholipids with aldehydic or carboxylic functions in the sn-2 position react with haloperidol, doxorubicin and chlorpromazine. Last but not least, distinct oxPl species may interact with specific binding sites and receptors leading to activation of individual signalling pathways. We intend here to highlight selected novel aspects in this field that have been published during the last year rather than present an exhaustive review of all findings in the area, which was published by our group last year [3] .
Role in atherogenesis and inflammation
The role of oxPl and inflammation has not only gained much attention with regard to atherosclerosis but has also moved beyond this chronic disease. Leitinger, Bochkov and colleagues previously demonstrated that oxPls counteract the lipopolysaccharide (LPS) pathway [4, 5] . In agreement with an anti-inflammatory role of oxPls, they reported that oxidized 1-palmitoyl-2-arachidonoylsn-glycero-3-phosphocholine (oxPAPC) interfered with the ability of LPS to bind to the LPS-binding protein (LBP) and to CD14, thus suppressing LPS-induced nuclear factor-kB (NF-kB)-mediated upregulation of inflammatory genes. Administration of this phospholipid to LPS-challenged mice alleviated tissue damage, protected mice from lethal endotoxin shock, and reduced the mortality rate. Similarly, in rodent models of acute necrotizing pancreatitis (ANP) oxPAPC exhibited a therapeutic effect and reduced the severity of the symptoms [6] . This effect was also attributed to an inhibition of LPS-induced signalling.
In line with these observations, Knapp et al. [7 ] found that oxPAPC inhibits the interaction of LPS with LPS-binding protein and CD14. It also reduces the phagocytotic activity of neutrophils and macrophages by a CD14-independent mechanism. In these experiments, however, administration of oxPAPC rendered mice highly susceptible to Escherichia coli peritonitis, which may contribute to mortality during Gram-negative sepsis in vivo. Thus, impairment of the host response to bacterial infections is likely to contribute to the overall harmful profile of phospholipid oxidation products in this case. The apparent discrepancy in the reported consequences of oxPl interactions with LPS may be associated with the dual role of LPS. It influences the status and development of the immune system on the one hand and is detrimental in (Gram negative) sepsis on the other hand.
Recent findings of Gharavi and colleagues [8] implicate a role for JAK2/STAT3 in atherogenesis. These authors report the activation of this pathway by oxidized phospholipids. 1-Palmitoyl-2-epoxyisoprostane-sn-glycero-3-phosphocholine, an oxidation product of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, induces c-Src kinase-dependent activation of JAK2 in endothelial cells and synthesis of chemotactic factors, such as interleukin (IL)-8. In turn, STAT3 activation and regulation of IL-8 transcription is dependent on JAK2 leading to enhanced levels of STAT3 activity in inflammatory regions of human atherosclerotic lesions. Since STAT3 activation is obviously involved in other chronic inflammatory diseases as well (such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus), the authors suggest that STAT3 activation by oxidized phospholipids could be an important interventional target for atherosclerosis and other diseases with inflammatory components.
Determination of oxPls might be useful in an assessment of cardiovascular risks. In blood, oxPls are found to be associated with apolipoprotein B-100-containing particles, especially lipoprotein (a) [Lp(a)]. Studies on interactions of lipoproteins with oxPl as well as on the biological effects of these complexes still reveal interesting novel aspects. In the Bruneck study [9] , plasma levels of oxPls (oxPl/apoB) and Lp(a) were measured in 765 subjects in 1995 and the incidence of cardiovascular disease (cardiovascular death, myocardial infarction, stroke, transient ischaemic attack) was assessed. High levels of oxPl were found to be associated with an increased risk of cardiovascular events, which was further enhanced by elevated lipoprotein-associated phospholipase activity. The atherogenicity of oxLDL/ apoB levels was similar to the effect of Lp(a). The similar power of both values as independent predictors could be partially explained by the ability of Lp(a) to preferentially bind oxidized phospholipids. It is noteworthy in this context, however, that Lp(a) carries both elevated levels of oxPls and platelet activating factor (PAF)-acetylhydrolase, an enzyme capable of hydrolysing oxPl [10] .
Oxidized phospholipid-induced signalling
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and 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC) are found in atherosclerotic lesions. POVPC is one of the most bioactive oxPl components. Pidkovka and colleagues [11 ] published a very important study demonstrating how oxPls contribute to the pathobiochemistry of atherosclerosis. They found that oxPls such as POVPC and oxPAPC switch the phenotype of smooth muscle cells (SMCs) in vivo to an inflammatory state. The respective lipids lead to changes in gene expression that are regulated by the transcription factor KLF4. The suppressed transcription of SMC differentiation marker genes induces expression of proinflammatory genes, enhances the rate of cellular proliferation and increases the synthesis of extracellular matrix proteins. POVPC and PGPC cause suppression of smooth muscle actin and myosin heavy chain expression while increasing expression of MCP-1, MCP-3, and cytolysin; siRNA targeting of transcription factor KLF4 reduced POVPC-induced suppression of SMC marker genes, which is also observed in KLF4 knockout cells.
In line with a pro-apototic activity of oxPl and with inhibition of this effect by enzymatic hydrolysis, we have found that POVPC and PGPC induce apoptosis and growth inhibition in vascular smooth muscle cells [12] . The phospholipids induce apoptosis under low serum conditions whereas under high serum conditions the resultant mixture is no longer apoptotic but antiproliferative [13] . An acid sphingomyelinase, which generates the second messenger ceramide, has been identified as a key upstream component of apoptotic signalling. It is activated within minutes, very likely on the protein level. Specific inhibition of acid sphingomyelinase gene expression abolishes activation of the signalling components downstream of this enzyme and as a consequence the apoptotic effect [12] . The initial molecular processes leading to acid sphingomyelinase activation and the contribution of the complex enzymatic network contributing to the apparent ceramide levels are still unknown (Fig. 2 ).
McIntyre's group [14 ] reports that LDL-associated phosphatidylcholine esterified with sn-2-azelaic acid at the sn-2 position is readily taken up by cells. This compound, one of the main phospholipid oxidation products in LDL, induces apoptosis of HL60 cells at low micromolar concentrations. Obviously, the intact phospholipid is required for signalling since this effect can be prevented by overexpression of PAF acetylhydrolase known for hydrolysing oxidized phospholipids with polar residues at the sn-2 position. sn-2-Azelaoyl phospholipids seem to exert a direct effect on mitochondria since they cause rapid swelling of these organelles and cytochrome c release leading to apoptosome formation followed by caspase 3 and caspase 9 activation. The apoptotic cells also serve as sources for oxPls [15] , which may contribute to an amplification of cell death in atherosclerosis.
Lipoproteins transport oxPl and deliver these compounds to cells. In addition, the lipoprotein particles influence the signalling of oxidized phospholipids in terms of pro-inflammatory and anti-inflammatory criteria [16 ] . It was shown that 1-palmitoyl-2-(5,6 epoxyisoprostanoyl)-sn-glycero-3-phosphocholine (PEIPC), an oxidation product of 1-palmitoyl-2-arachidonyl-sn-3-glycero-phosphorylcholine, induces an inflammatory response in endothelial cells, which is due to induction of specific genes. This effect was suppressed after preincubation with HDL. The same lipoprotein fraction also reduced the oxPl-dependent chemotactic activity and monocyte binding. In addition to its cholesterol-lowering effect, these phenomena may add to the list of protective properties of HDL.
Truncated phospholipids on the one hand and epoxyisoprostane phospholipids on the other hand specifically modulate the transcription of several genes. Berliner's group [17] reported that the levels of OKL38 mRNA (also named bone marrow-derived growth factor), a tumour growth inhibitor, were increased by oxPAPC and 1-palmitoyl-2-epoxyisoprostanoyl-sn-glycero-3-phosphocholine (PEIPC). This effect appears to be limited to distinct oxidized phospholipids since PEIPC, but neither POVPC nor PGPC, induced Nrf2 translocation and OKL38 expression. We analysed the effects of POVPC and PGPCs on monocyte transcription using microarrays and found that these phospholipids enhanced transcription of CCl11, MMP1 and several other genes. Most remarkably, many of these changes matched the effects mediated by ceramide (M. Blaess, A. Hermetter, H.P. Deigner, unpublished data).
Receptors for oxidized phospholipids
Specific receptor binding of oxPl is the subject of an ongoing debate [3] . Evidence that oxidized phospholipids may act by binding to a G protein-coupled receptor (GPCR) has previously been provided by Parhami et al. [18, 19] . These authors demonstrated that minimally modified LDL stimulated a putative Gs-coupled receptor, thus increasing cyclic AMP (cAMP) levels in endothelial cells.
More recently, the prostaglandin E2 (PGE2) receptor EP2, a Gs-linked GPCR, has been added to the list of binding sites for oxidized phospholipids. Activation of endothelial cells by the oxidized phospholipid PEIPC may occur via this receptor and provide a mechanism by which monocytes/macrophages are recruited to the subendothelial space: Li et al. [20] found that PEIPC induced monocyte adhesion to endothelial cells by activating EP2, leading to increased cAMP levels and activation of protein kinase A. Further signalling may proceed via activation of R-Ras and 1-integrins, enhancing surface expression of CS-1 fibronectin capable of interacting with VLA-4 on monocytes.
It has previously been shown that POVPC binds to human macrophages via the PAF receptor (PAF-R). Occupation of the PAF-R by the oxidized phospholipids modifies the transcription levels of pro-inflammatory genes [21] such as IL-8. Other genes, however, including those encoding for matrix metalloproteinase-13 and 15-lipoxygenase, that are stimulated by binding of PAF to its receptor were not affected by the phospholipids. Thus, it was suggested that POVPC signalling in macrophages occurs only partially via the PAF-R.
A very interesting study reporting on the molecular mechanisms of macrophage interaction with oxidized cell membranes has been published very recently. According to the 'lipid whisker model' of Greenberg et al. [22 ] , macrophage binding to cell surfaces is mediated by the interaction of CD36 with the oxidized phospholipid acyl chains protruding from the plasma membrane. Recognition of the phospholipids head group is not involved. From studies performed with oxidized phosphatidylcholine and ethanolamine, Berliner's group [1] arrived at a similar conclusion. They found that binding of monocytes to endothelial cells is solely dependent on the type of the oxidized fatty acid in the sn-2 position of the phospholipid and is not affected by the structure of the polar head group.
Aldehydo-phospholipids are capable of reacting with NH 2 groups of proteins and phospholipids to form new epitopes and to cause immune reactions [23, 24] . An unspecific occupation of receptors and partial antagonisms with natural or specific synthetic ligands may be due to an aldehyde amino reaction and Schiff base formation. The identification of the modified targets and their relevance to signalling are the subjects of intense research in our laboratory. Along these lines, investigations are currently being performed to characterize the oxPl-associated proteome of vascular cells. For this purpose, we have developed specific molecular tools to study uptake, distribution, cellular localization and reactivity of oxPl [25 ] (Fig. 3) .
Metabolism of oxidized phospholipids
It has been known for years that oxidized fatty acyl chains can be released from the sn-2 position of membrane phospholipids by PAF-acetylhydrolase (PAF-AH) in plasma and an intracellular type II PAF acetylhydrolase. The substrate preferences of plasma PAF-AH and the intracellular enzyme which is found in the cytosol as well as in membrane-associated form are very similar. Overexpression of the type II enzyme, which shows elevated expression levels in epithelial cells, was previously shown to suppress oxidative stress-induced apoptosis. Arai's group [26] very recently reported on the effect of PAF-AH (II) deficiency in mice (Pafah2 À/À mice). While Pafah2 À/À mice apparently developed normally and were phenotypically indistinguishable from wild-type mice, mouse embryonic fibroblasts derived from Pafah2 À/À mice were more sensitive to tert-butylhydroperoxide treatment than those derived from wild-type animals. This effect was attributed to the activity of oxPl. Interestingly, Pafah2 À/À mice displayed impaired recovery from CCl 4 -induced hepatic injury. These data support a protective role of PAF-AH against the overt effects of oxPl in vivo and it would be interesting to test the oxPl effects on lifespan in animal models.
As tools for systems biology approaches are becoming increasingly available, it will be possible to analyse complex scenarios such as formation, metabolism and partitioning of oxPl and its metabolites together with the associated signal transduction phenomena. Oxidative stress may be reflected by enhanced concentrations of oxPl and their oxidized fatty acid components as well as their conjugates with proteins and other lipids. Efforts are already being made to apply metabolomics aiming at a comprehensive characterization of virtually all relevant lipid species. In addition to lipidome analyses, an extensive mapping of cell components on the levels of the transcriptome, the proteome and the apparent enzyme activities will ultimately lead to a picture of the signalling networks that mediate the biological effects of oxPl.
So far it has not been known whether or to what extent the aldehyde function in phospholipids such as POVPC [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine] is enzymatically processed further. The aldehyde function, however, is a prerequisite for certain biological properties of this molecule. Phospholipid aldehydes such as POVPC activate binding of monocytes by endothelial cells [27] and increase the production of monocyte chemotactic factors. It has previously been shown that reduction of the aldehyde group to the corresponding alcohol abolished oxPl-induced stimulation of monocyte binding [1] . Spite and colleagues [28] recently reported that POVPC is reduced efficiently by mammalian aldoketo reductases (AKRs; AKR1A and B families). Among these enzymes, which may catalyse tissue-specific metabolism of phospholipid aldehydes, the human aldose reductase AKR1B1, but not AKR6 or ARK7, shows the highest catalytic activity.
Conclusion
OxPls may show detrimental as well as beneficial cellular effects. Key components of their intracellular signal transduction have been identified that mediate the observed cellular effects including inflammation, apoptosis and phenotype switching; however, the fundamental molecular mechanisms underlying signal initiation and propagation, such as lipid mediators and complex enzyme networks, are still far from clear. An advancement in this field can be expected from studies that are based on well defined synthetic and labelled oxPl species and the modern omics techniques of systems biology. They will undoubtedly help establish a molecular network of the cellular signalling components that are involved in the mediation of the pathophysiological effects of oxPl and thus represent potential pharmaceutical targets.
